Preamendment device, like the metal-on-metal hip systems, is classified as a Class III or higher risk devices by the US Food and Drug Administration. On 1976, FDA was given a premarket authority over medical devices, and equipments marketed before that were considered preamendment device. The FDA has 510(k) premarket notification program which regulates these devices. But, patients who had metal-on-metal hip implants are now filing lawsuits against manufacturers after experiencing some complications. Based on the article published on New York Times, the metal-on-metal device complaints have surged this year
, greater than the combined numbers of the past four years.
The 510(k) approval process of the FDA was questioned by the Institute of Medicine, saying that the process does not provide a reliable and premarket screen of the safety and effectiveness of devices submitted for approval. In response to the report, FDA acknowledged the agencys need to be open to additional proposals and approaches for continued improvement of our device review programs.
United Kingdoms Medicines and Healthcare products Regulatory Agency issued a medical device alert on April 2010, which includes specific follow-up recommendations for recipients of the MoM hip implants. Blood tests and imaging for patients experiencing pain are included in the recommendations. DePuy Orthopedics voluntarily recalled their DePuy ASR hip on August 2010. The UK joint registry had new, unpublished data indicating the revision rates of the DePuy ASR hip within 5 years were roughly 13 percent.
The safety and effectiveness of metal-on-metal hip implants is further evaluated by the FDA by looking and assessing at different areas. Manufacturers of the hip systems were asked to submit device retrieval analyses to the agency. FDA continues to review published literature, Medical Device Reports, post-approval study reports and data from several orthopedic device registries. Through this, they can better understand the adverse events linked with metal debris on MoM hip systems.
Blood tests and special imaging are not required for patients with MoM hip implants if they are not manifesting symptoms of device complication. As per FDA recommendation, patients with negative symptoms continue to follow-up with their orthopedic surgeon. Prompt visit to an orthopedic surgeon once signs and symptoms are observed is also recommended in order to prevent progression to major situations, like a DePuy hip recall.
, greater than the combined numbers of the past four years.
The 510(k) approval process of the FDA was questioned by the Institute of Medicine, saying that the process does not provide a reliable and premarket screen of the safety and effectiveness of devices submitted for approval. In response to the report, FDA acknowledged the agencys need to be open to additional proposals and approaches for continued improvement of our device review programs.
United Kingdoms Medicines and Healthcare products Regulatory Agency issued a medical device alert on April 2010, which includes specific follow-up recommendations for recipients of the MoM hip implants. Blood tests and imaging for patients experiencing pain are included in the recommendations. DePuy Orthopedics voluntarily recalled their DePuy ASR hip on August 2010. The UK joint registry had new, unpublished data indicating the revision rates of the DePuy ASR hip within 5 years were roughly 13 percent.
The safety and effectiveness of metal-on-metal hip implants is further evaluated by the FDA by looking and assessing at different areas. Manufacturers of the hip systems were asked to submit device retrieval analyses to the agency. FDA continues to review published literature, Medical Device Reports, post-approval study reports and data from several orthopedic device registries. Through this, they can better understand the adverse events linked with metal debris on MoM hip systems.
Blood tests and special imaging are not required for patients with MoM hip implants if they are not manifesting symptoms of device complication. As per FDA recommendation, patients with negative symptoms continue to follow-up with their orthopedic surgeon. Prompt visit to an orthopedic surgeon once signs and symptoms are observed is also recommended in order to prevent progression to major situations, like a DePuy hip recall.
Source...